The mechanism of COVID-19 associated coagulopathy: a prospective cohort study

Circulating microparticles as biomarkers in COVID-19 associated coagulopathy: a prospective cohort study - The role of microparticles in coagulopathy of COVID-19: a prospective cohort study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042717

Enrollment

100

Registered

2020-12-10

Start date

2020-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients admitted with COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients admitted with COVID-19

Exclusion criteria

Exclusion criteria: (1) patients in which informed consent could not be obtained from the person or close relatives (2) patients who have other infectious diseases (3) patients with end-stage heart failure( defined as NYHA class4) (4) patients with end-stage liver failure (defined as Child-Pugh classification C) (5) patients with progressive cancer, or patients undergoing cancer treatment (6) patients who are pregnant (7) patients who have participated in this study (8) patients who are diagnosed as COVID-19 accidentally and need emergency treatment for other diseases

Design outcomes

Primary

Measure	Time frame
The level of Tissue factor bearing microparticles	—

Countries

Japan

Contacts

Public ContactYudai Iwasaki

Tohoku university hospital Department of Anesthesiology and Perioperative Medicine

yudai.i0213@gmail.com0227177000

Outcome results